4P-PHARMA
29.4.2024 06:41:26 CEST | Business Wire | Press release
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/
(Graphic: Business Wire)
With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.
Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."
This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.
This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.
Revital Rattenbach concludes: "After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Site internet : https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma/
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424933193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Opengear Expands Reach Through Pan-European Distribution Agreement with Ingram Micro29.9.2026 09:01:00 CEST | Press release
Opengear’s network resilience solutions now available across 20 European markets Opengear, a Digi International company (NASDAQ: DGII) and global leader in out-of-band management solutions, has signed its first pan-European distribution agreement with Ingram Micro, one of the world’s largest technology distributors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929668925/en/ Opengear Expands Reach Through Pan-European Distribution Agreement with Ingram Micro The agreement will give resellers in participating Ingram Micro countries access to Opengear’s portfolio, supported by Ingram Micro's regional infrastructure, logistics capabilities and partner network. This expands Opengear’s existing reach in the UK, Ireland, Spain, Germany, Italy, France, Belgium and Luxembourg, and brings its network resilience platform to resellers and end-users in additional European markets, such as Switzerland, Hungary, and Czech Republic. “T
Freemarket and Axiym launch LIQUI-DT™ – real-time business access to primary-market USD₮ from Tether29.9.2026 08:00:00 CEST | Press release
Freemarket and Axiym today launched a world-first service that gives businesses 24/7 real-time access to freshly minted, primary-market USD₮ issued by Tether. LIQUI-DTTM gives businesses compliant access to primary market stablecoins inside a fully regulated payment ecosystem via Freemarket’s global payment network. In audited trials, clients have minted or burned more than $300 million to date. Institutional users and high-volume traders will benefit from superior price certainty and direct liquidity giving them budgetary control. As the USD₮ is minted directly in the primary market, treasury and compliance teams have clear provenance for internal reporting 1. The LIQUI-DT service works because while no single party owns the whole stack, it is integrated into the Freemarket network. The combination of Freemarket’s compliant fiat rails and payment network, Axiym’s liquidity engine and on-chain settlement layer and Tether’s primary market issuance creates a regulated payments network wi
Estonia and Owkin Partner to Advance Sovereign AI in Biology29.9.2026 08:00:00 CEST | Press release
Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metrosert, Estonia’s state-owned applied research organisation. The collaboration will evaluate how K Pro, Owkin’s AI scientist platform, can help approved researchers work with complex Estonian health data inside secure national infrastructure, enabling reproducible analysis, and faster generation of scientific insight while preserving data sovereignty. The first phase will focus on selected Estonian health-data cohorts, with Owkin and Metrosert also exploring high-value research areas including oncology, where linked clinical, molecular, imaging and treatment-outcome data could support future biomedical research. Estonia has built one of the world’s most advanced digital public infrastructures and holds population-scale health and biomedical data assets. The partnership will explore how these foundations can
Jumio Completes Worldwide Rollout of selfie.DONE™, Bringing Privacy-Focused Reusable Identity to EMEA29.9.2026 07:00:00 CEST | Press release
Selfie-first onboarding eliminates unnecessary ID scans for trusted users, backed by the global Jumio Identity Graph, consent-based privacy and real-time compliance Jumio, the leading provider of AI-powered identity intelligence, today announced the expansion of its reusable identity solution, selfie.DONE, across Europe, the Middle East, and Africa. This launch marks the final phase of Jumio’s selfie.DONE rollout, following successful launches in Latin America, North America, and Asia-Pacific — making true reusable identity available worldwide wherever Jumio operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928989719/en/ In regulated EMEA markets, organizations face the dual challenge of eliminating onboarding friction while adhering to stringent privacy standards and regulatory frameworks, including GDPR, PSD2, AMLD, and other evolving regulatory compliance requirements. selfie.DONE addresses this challenge with a
Copeland to Showcase Solutions for Data Centers, Heat Pumps and Sustainable Refrigeration at Chillventa29.9.2026 07:00:00 CEST | Press release
Technologies designed to help customers improve efficiency, reduce emissions and address evolving cooling, heating and cold chain needs Copeland, a global leader in compression technologies and controls solutions, today announced its participation at Chillventa 2026, taking place Oct. 13-15 in Nuremberg, Germany. From growing data center cooling demands to increased adoption of heat pumps and natural refrigerants, customers across Europe are navigating rapid change. Copeland will showcase technologies designed to address the region's evolving heating, cooling and refrigeration requirements. As demand for energy-efficient cooling, electrified heating and sustainable industrial operations grows across Europe, Copeland continues to invest in the technologies, capabilities and partnerships needed to help customers navigate changing regulatory requirements and work toward their sustainability objectives. Copeland has made a series of strategic investments to support Europe's long-term energ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom